Cell type-selective carriers for targeted pharmacological inhibition of Rho-/actin-dependent leukocyte recruitment into the alveolar space after blunt chest trauma (A04)

细胞类型选择性载体，用于在钝性胸部创伤后对 Rho/肌动蛋白依赖性白细胞募集至肺泡腔进行靶向药理抑制 (A04)

• 批准号: 269283320
• 金额: --
• 依托单位: Institut für Experimentelle und Klinische Pharmakologie,Toxikologie und Naturheilkunde
• 依托单位国家: 德国
• 项目类别: Collaborative Research Centres
• 财政年份: 2015
• 资助国家: 德国
• 起止时间: 2014-12-31 至 2017-12-31
• 项目状态: 已结题
• 来源: https://gepris.dfg.de/gepris/projekt/269283320?language=en
• 关键词: Cell; type; selective; carriers; targeted

(Cell type-selective carriers for targeted pharmacological inhibition of Rho-/actin-dependent leukocyte recruitment into the alveolar space after blunt chest trauma) focuses on strategies to selectively modulate recruitment and function of both macrophages and neutrophils in the alveolar space. The project builds on the discovery of monocyte/macrophage-selective carriers (C3botE174Q) to transfer Rho-, actin-, and CXCR2-inhibitors into the cells. Neutrophil-selective transporters with similar therapeutic options will be developed and their effects on the inflammatory response determined in a murine thorax trauma model. Furthermore, targeted delivery of contrast agents will enable lifetime monitoring of cell migration by MRI.

(Cell用于靶向药理学抑制钝性胸部创伤后Rho-/肌动蛋白依赖性白细胞募集到肺泡腔中的类型选择性载体）集中于选择性调节肺泡腔中巨噬细胞和嗜中性粒细胞的募集和功能的策略。该项目建立在单核细胞/巨噬细胞选择性载体（C3 botE 174 Q）的发现基础上，将Rho-，肌动蛋白-和CXCR 2-抑制剂转移到细胞中。将开发具有相似治疗选择的嗜中性粒细胞选择性转运蛋白，并在小鼠胸部创伤模型中确定其对炎症反应的影响。此外，造影剂的靶向递送将使得能够通过MRI对细胞迁移进行寿命监测。